Refine
Year of publication
Document Type
- Preprint (824)
- Article (694)
- Conference Proceeding (7)
- Working Paper (2)
- Part of a Book (1)
Has Fulltext
- yes (1528)
Is part of the Bibliography
- no (1528)
Keywords
- Heavy Ion Experiments (22)
- Hadron-Hadron Scattering (14)
- Hadron-Hadron scattering (experiments) (12)
- LHC (10)
- Heavy-ion collision (6)
- Heavy-ion collisions (6)
- Jets (6)
- SARS-CoV-2 (6)
- Heavy Quark Production (5)
- ALICE experiment (4)
- COVID19-NMR (4)
- Collective Flow (4)
- Heavy Ions (4)
- Quark-Gluon Plasma (4)
- Solution NMR spectroscopy (4)
- 5′-UTR (3)
- ALICE (3)
- Diffraction (3)
- Elastic scattering (3)
- Jets and Jet Substructure (3)
- Quarkonium (3)
- meningioma (3)
- neurodegeneration (3)
- pp collisions (3)
- Beam Energy Scan (2)
- Beauty production (2)
- COVID-19 (2)
- Cancer genomics (2)
- Charm physics (2)
- Chiral Magnetic Effect (2)
- Clinical Trials and Observations (2)
- Collectivity (2)
- Correlation (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy-Ion Collision (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Monte Carlo (2)
- NR4A2 (2)
- PPARγ (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Polarization (2)
- Pulmonary embolism (2)
- QCD (2)
- Quark Gluon Plasma (2)
- RHIC (2)
- Relativistic heavy-ion collisions (2)
- SFAP (2)
- STAR (2)
- Shear viscosity (2)
- Single electrons (2)
- Systematic Uncertainty (2)
- Time Projection Chamber (2)
- UAV (2)
- clinically important restrictions and symptoms (2)
- drug discovery (2)
- epilepsy (2)
- fragment screening (2)
- guidelines (2)
- hematopoietic stem cell transplantation (2)
- nuclear receptor (2)
- observational study (2)
- polypharmacology (2)
- rare disease (2)
- soil erosion (2)
- structural biology (2)
- transcription factor (2)
- 140Ce (1)
- 5'-UTR (1)
- 5_SL4 (1)
- 900 GeV (1)
- ABC transporters (1)
- ALICE LHC (1)
- ALICE detector (1)
- ARDS (1)
- ATAD2 (1)
- ATPases (1)
- Advanced biliary tract cancer (1)
- Alzheimer’s disease (1)
- Analysis and statistical methods (1)
- Anti-nuclei (1)
- Antibiotic Resistance (1)
- Antibiotics (1)
- Atherosclerosis (1)
- B-slope (1)
- BET inhibitors (1)
- BRD2 (1)
- BRD4 (1)
- BROMO-10 (1)
- BTC (1)
- Bacillus (1)
- Bacterial pathogens (1)
- Balance function (1)
- Baryonic resonances (1)
- Beam energy scan (1)
- Biochemistry and chemical biology (1)
- Biodiversity (1)
- Biogeography (1)
- Bipolar disorder (1)
- Boosted Jets (1)
- Brain metastasis (1)
- CD74 (1)
- COVID (1)
- Calorimeters (1)
- Cancer (1)
- Cancer genetics (1)
- Canonical suppression (1)
- Cardiomyocyte signaling pathways (1)
- Cardioprotection (1)
- Cardiovascular disease (1)
- Cardiovascular diseases (1)
- Carrier-bound fibrin sealant (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge correlations (1)
- Charge fluctuations (1)
- Charged-particle density (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Chemical tools (1)
- Chiral magnetic effect (1)
- Circadian (1)
- Circulating MiRNA (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collagen hemostat (1)
- Collective Flow, (1)
- Comorbidities (1)
- Comparison with QCD (1)
- Conformational trapping (1)
- Coronary heart disease (1)
- Covid19-nmr (1)
- Critical care (1)
- Critical point (1)
- DIPSHIFT (1)
- Data management (1)
- Data processing methods (1)
- Data sharing (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Diagnostic markers (1)
- Direct oral anticoagulation (1)
- Disease Activity (1)
- Drug safety (1)
- Drug screening (1)
- Drug targeting (1)
- E. colo (1)
- Early Rheumatoid Arthritis (1)
- Ecology (1)
- Ecophysiology (1)
- Ecosystems (1)
- Electromagnetic transitions (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Endothelial permeability (1)
- Entomology (1)
- Environment (1)
- Experimental models of disease (1)
- Extracellular RNA (eRNA) (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flow (1)
- Forschung (1)
- Forward physics (1)
- Freezeout (1)
- G protein-coupled receptor (GPCR) (1)
- G protein-coupled receptors (1)
- GVHD (1)
- Genetics (1)
- Genome-wide association studies (1)
- Genomic instability (1)
- Germany (1)
- Glioblastoma survival (1)
- Groomed jet radius (1)
- HBT (1)
- HLA class II (1)
- HLA peptidome (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hand-foot syndrome (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Health risk analysis (1)
- Heart regeneration (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Heavy-ion detectors (1)
- Heavy-ion reactions (1)
- Hemostatics (1)
- HepG2 (1)
- Hif1α (1)
- High-throughput screening (1)
- Higher moments (1)
- HoLEP (1)
- Holmium laser enucleation (1)
- In vitro selection (1)
- Incidental prostate cancer (1)
- Inclusive spectra (1)
- Induced pluripotent stem cells (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Ischemia–reperfusion injury (1)
- Italy (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- KCGS (1)
- KPS (1)
- LanI Protein (1)
- Lantibiotic (1)
- Lantibiotic Immunity (1)
- Large Hadron Collider (1)
- Large detector systems for particle and astroparticle physics (1)
- Lehre (1)
- Lipid metabolism (1)
- Lipoprotein (1)
- Liver Fibrosis (1)
- Liver resection (1)
- Low-molecular-weight heparin (1)
- Lymphocytes (1)
- Lymphoid Neoplasia (1)
- Lymphoid tissues (1)
- MACS (1)
- MODY (1)
- Malignant meningioma (1)
- Marine chemistry (1)
- Material budget (1)
- Medicinal chemistry (1)
- Membrane protein (1)
- Meningioma (1)
- Metabolic syndrome (1)
- MiR-29 (1)
- MicroRNAs (miRNAs) (1)
- Microbiome (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Models & methods for nuclear reactions (1)
- Molecular medicine (1)
- Molecular modelling (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Myeloid Neoplasia (1)
- Myocardial infarction (1)
- N-acetylcysteine (1)
- NK cell (1)
- NK cell subset (1)
- NMR (1)
- NMR spectroscopy (1)
- NR4A3 (1)
- Nanobody (1)
- Neolithic (1)
- Neural network (1)
- Neuropilin (1)
- Neutron physics (1)
- Next-generation sequencing (1)
- Nonflow (1)
- Nuclear Magnetic Resonance (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- ORL (1)
- Observation (1)
- Oncology (1)
- Orphan nuclear receptor (1)
- Otorhinolaryngology (1)
- Outcome (1)
- Outcomes research (1)
- PCV (1)
- PDGFRβ (1)
- PYTHIA (1)
- Palaeoceanography (1)
- Palaeoclimate (1)
- Parkinson’s disease (1)
- Particle and Resonance Production (1)
- Particle production (1)
- Patterns of care (1)
- Pb–Pb (1)
- Performance of High Energy Physics Detectors (1)
- Periodontitis (1)
- Phage display (1)
- Phylogenomics (1)
- Population genetics (1)
- Preclinical research (1)
- Predictive markers (1)
- Production Cross Section (1)
- Prognostic markers (1)
- Prognostic models (1)
- Properties of Hadrons (1)
- Prostate cancer (1)
- Protein Structure (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Psychiatry (1)
- Pyogenic spondylodiscitis (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quark–gluon plasma (1)
- RNA (1)
- RNA genome (1)
- RNASolution-state NMR (1)
- RXRα (1)
- Radiative capture (1)
- Radiotherapy (1)
- Randomized controlled trial (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Remote ischemic conditioning (1)
- Research (1)
- Residency (1)
- Resolution Parameter (1)
- Resonance reactions (1)
- Resonances (1)
- Rheumatoid Arthritis (1)
- Ribosome display (1)
- Risk factor (1)
- Routine Medical Care (1)
- Rpo4/7 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCT (1)
- SKALE score (1)
- SL1 (1)
- SL5a (1)
- SL5b (1)
- SL5b + c (1)
- SL5c (1)
- STAMPE2 (1)
- Salivary gland carcinoma (1)
- Seasonal variation (1)
- Shannon index (1)
- Single muons (1)
- Socio-ecology (1)
- SoftDrop (1)
- Solar insolation (1)
- Sorafenib (1)
- SpaI (1)
- Specialist training (1)
- Spin alignment (1)
- Splitting function (1)
- Ste2p (1)
- Strangeness enhancement (1)
- Stroke (1)
- Structural biology and molecular biophysics (1)
- Subtilin (1)
- Suicide (1)
- Sunlight (1)
- Surgery (1)
- Sweden (1)
- TIRADS (1)
- TR (1)
- TTW nodules (1)
- TUR-P (1)
- Target identification (1)
- Target validation (1)
- Taxonomy (1)
- Teaching (1)
- Teeth (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Thrombosis (1)
- Tools and ressources (1)
- Topology (1)
- Tracking (1)
- Transition radiation detector (1)
- Translational research (1)
- Transurethral resection of the prostate (1)
- Transverse Momentum (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment (1)
- Trigger (1)
- Tumor infiltrating lymphocytes (1)
- Unemployment (1)
- University hospitals (1)
- Universitätskliniken (1)
- VEGF (1)
- VEGF receptors (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- Vector Boson Production (1)
- Viral infection (1)
- Wealth Losses (1)
- Weiterbildung (1)
- Wide rapidity coverage (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Zuckerkandl’s tubercle (1)
- accident (1)
- alleles (1)
- allostery (1)
- anaemia (1)
- androgen receptor (1)
- antibodies (1)
- anticonvulsants (1)
- autism spectrum disorder (1)
- autistic disorder (1)
- azacitidine (1)
- b-cell lymphomas (1)
- bendamustine (1)
- biogeographic legaciese (1)
- biomarker (1)
- bromodomain (1)
- bromodomain inhibitor (1)
- c-kit (1)
- capture (1)
- carbon and proton assignments (1)
- cardiocerebral resuscitation (1)
- cardiopulmonary resuscitation (1)
- castration-resistant prostate cancer (1)
- cell-free expression (1)
- cerium (1)
- charge transfer (1)
- chemogenomic set (1)
- chemotherapy (1)
- chemotherapy regimen (1)
- child (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- chromatin (1)
- cirrhosis (1)
- clinical practice (1)
- cofactor recruitment (1)
- computational chemistry (1)
- copy number polymorphism (1)
- coronavirus (1)
- cross-section (1)
- cryo-EM (1)
- cytotoxicity (1)
- dE/dx (1)
- detector (1)
- dexamethasone (1)
- differential scanning fluorimetry (1)
- diffuse low-grade glioma (1)
- diffusion-weighted magnetic resonance imaging (1)
- domestication (1)
- double access (1)
- drug target (1)
- druggable genome (1)
- dynamics (1)
- ectosomes (1)
- elderly (1)
- epigenetic (1)
- everolimus (1)
- evolution (1)
- exercise (1)
- exosomes (1)
- experimental results (1)
- experiments (1)
- extracellular vesicles (1)
- fluorescence (1)
- follow-up (1)
- forest classification (1)
- forest functional similarity (1)
- fragment-based design (1)
- fragment-based drug design (1)
- freshwater ecosystems (1)
- gastric cancer (1)
- gastrointestinal stromal tumours (1)
- gene flow (1)
- genes (1)
- genetics (1)
- genome (1)
- genotype (1)
- genotype determination (1)
- glioblastoma (1)
- glioblastoma survival (1)
- glioma microenvironment (1)
- global change (1)
- habitat destruction (1)
- health (1)
- health-related quality of life (1)
- health-relatedquality of life (1)
- heavy ion experiments (1)
- heavy-ion collisions (1)
- hepatocyte nuclear factor 4α (1)
- hepatocyte transplantation (1)
- heterodimer (1)
- homodimer (1)
- homogeneous time-resolved FRET (HTRF) (1)
- hotspot loci (1)
- hypoxia (1)
- immune infiltration (1)
- immune reconstitution (1)
- injury (1)
- insect abundance (1)
- juvenile myelomonocytic leukemia (1)
- kinase inhibitor (1)
- land use (1)
- land-use change (1)
- leukapheresis (1)
- leukemia (1)
- lockdown (1)
- long-term research (1)
- lymphoma (1)
- magic angle spinning (1)
- membrane protein (1)
- membrane proteins (1)
- metabolic syndrome (1)
- metastatic renal cell carcinoma (1)
- miRNA (1)
- microdeletions (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- molecular machines (1)
- monitoring (1)
- montelukast (1)
- multiple sclerosis (1)
- multiplexed immunofluorescence (1)
- multiscale (1)
- multitarget drugs (1)
- mutation (1)
- n_TOF (1)
- neoadjuvant chemoradiotherapy (1)
- neurodevelopmental (1)
- neutron (1)
- nuclear magnetic resonance (NMR) (1)
- nuclear receptor related-1 (1)
- nuclear receptor-related 1 (1)
- nucleosynthesis (1)
- object-based classification (1)
- oral cavity cancer (1)
- p+p collisions (1)
- pediatric intensive care (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- pharmacokinetics (1)
- pharmacophore model (1)
- phase IV (1)
- phenotype (1)
- phenotypic screening (1)
- photochemistry (1)
- photogrammetry (1)
- photolabile protecting groups (1)
- phylogenetic community distance (1)
- phylogeny (1)
- pole concept of goiter growth (1)
- portal hypertension (1)
- posterior horn (1)
- posteroinferior horn (1)
- pranlukast (1)
- predictive biomarker (1)
- primary active transporters (1)
- protein folding (1)
- protein kinase (1)
- pulmonary embolism (1)
- quark gluon plasma (1)
- recurrence pattern (1)
- red blood cells (1)
- remote sensing (1)
- renin-angiotensin system (1)
- reproducibility (1)
- retinoid X receptor (1)
- rigor (1)
- risk of malignancy (1)
- rituximab (1)
- s-process (1)
- sarcoma (1)
- second-line (1)
- secondary chemical shifts (1)
- seizures (1)
- sequence alignment (1)
- signature (1)
- single nucleotide polymorphism (1)
- small molecules (1)
- solid-state NMR (1)
- soluble epoxide hydrolase (1)
- spectra (1)
- speech reports (1)
- ssFLYA (1)
- standardization (1)
- stearic acid (1)
- taller-than-wide (1)
- temozolomide (1)
- tense (1)
- therapeutic anticoagulation (1)
- threats (1)
- transfusion (1)
- trauma (1)
- tropical forests (1)
- type 2 diabetes (1)
- tyrosine kinase inhibitors (1)
- understudied kinase (1)
- zafirlukast (1)
- Υ suppression (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1295)
- Frankfurt Institute for Advanced Studies (FIAS) (1165)
- Informatik (1023)
- Medizin (76)
- Biochemie, Chemie und Pharmazie (16)
- Biochemie und Chemie (9)
- Biowissenschaften (9)
- Geowissenschaften (8)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (7)
- Pharmazie (5)
Background Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights.
Objective To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion.
Methods A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived.
Results The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1–3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for particular aspects of the disease, especially comorbidity and shared decision-making with the patient. Levels of evidence had increased for many items compared with the 2010 recommendations, and levels of agreement were very high for most of the individual recommendations (≥9/10).
Conclusions The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
Despite an increasing demand for Burgundy truffles (Tuber aestivum), gaps remain in our understanding of the fungus’ overall lifecycle and ecology. Here, we compile evidence from three independent surveys in Hungary and Switzerland. First, we measured the weight and maturity of 2,656 T. aestivum fruit bodies from a three-day harvest in August 2014 in a highly productive orchard in Hungary. All specimens ranging between 2 and 755 g were almost evenly distributed through five maturation classes. Then, we measured the weight and maturity of another 4,795 T. aestivum fruit bodies harvested on four occasions between June and October 2015 in the same truffière. Again, different maturation stages occurred at varying fruit body size and during the entire fruiting season. Finally, the predominantly unrelated weight and maturity of 81 T. aestivum fruit bodies from four fruiting seasons between 2010 and 2013 in Switzerland confirmed the Hungarian results. The spatiotemporal coexistence of 7,532 small-ripe and large-unripe T. aestivum, which accumulate to ~182 kg, differs from species-specific associations between the size and ripeness that have been reported for other mushrooms. Although size-independent truffle maturation stages may possibly relate to the perpetual belowground environment, the role of mycelial connectivity, soil property, microclimatology, as well as other abiotic factors and a combination thereof, is still unclear. Despite its massive sample size and proof of concept, this study, together with existing literature, suggests consideration of a wider ecological and biogeographical range, as well as the complex symbiotic fungus-host interaction, to further illuminate the hidden development of belowground truffle fruit bodies.
Background: Despite improvements in liver surgery over the past decades, hemostasis during hepatic resections remains challenging. This multicenter randomized study compares the hemostatic effect of a collagen hemostat vs. a carrier-bound fibrin sealant after hepatic resection.
Methods: Patients scheduled for elective liver resection were randomized intraoperatively to receive either the collagen hemostat (COLL) or the carrier-bound fibrin sealant (CBFS) for secondary hemostasis. The primary endpoint was the proportion of patients with hemostasis after 3 min. Secondary parameters were the proportions of patients with hemostasis after 5 and 10 min, the total time to hemostasis, and the complication rates during a 3 months follow-up period.
Results: A total of 128 patients were included. In the COLL group, 53 out of 61 patients (86.9 %) achieved complete hemostasis within 3 min after application of the hemostat compared to 52 out of 65 patients (80.0 %) in the CBFS group. The 95 % confidence interval for this difference [−6.0 %, 19.8 %] does not include the lower noninferiority margin (−10 %). Thus, the COLL treatment can be regarded as noninferior to the comparator. The proportions of patients with hemostasis after 3, 5, and 10 min were not significantly different between the two study arms. Postoperative mortality and morbidity were similar in both treatment groups.
Conclusion: The collagen hemostat is as effective as the carrier-bound fibrin sealant in obtaining secondary hemostasis during liver resection with a comparable complication rate.
Purpose: The extent of preoperative peritumoral edema in glioblastoma (GBM) has been negatively correlated with patient outcome. As several ongoing studies are investigating T-cell based immunotherapy in GBM, we conducted this study to assess whether peritumoral edema with potentially increased intracranial pressure, disrupted tissue homeostasis and reduced local blood flow has influence on immune infiltration and affects survival.
Methods: A volumetric analysis of preoperative imaging (gadolinium enhanced T1 weighted MRI sequences for tumor size and T2 weighted sequences for extent of edema (including the infiltrative zone, gliosis etc.) was conducted in 144 patients using the Brainlab® software. Immunohistochemical staining was analyzed for lymphocytic- (CD 3+) and myelocytic (CD15+) tumor infiltration. A retrospective analysis of patient-, surgical-, and molecular characteristics was performed using medical records.
Results: The edema to tumor ratio was neither associated with progression-free nor overall survival (p=0.90, p=0.74). However, GBM patients displaying IDH-1 wildtype had significantly higher edema to tumor ratio than patients displaying an IDH-1 mutation (p=0.01). Immunohistopathological analysis did not show significant differences in lymphocytic or myelocytic tumor infiltration (p=0.78, p=0.74) between these groups.
Conclusion: In our cohort, edema to tumor ratio had no significant correlation with immune infiltration and outcome. However, patients with an IDH-1wildtype GBM had a significantly higher edema to tumor ratio compared to their IDH-1 mutated peer group. Further studies are necessary to elucidate the underlying mechanisms.
Background; Salivary gland carcinomas (SGC) cover a heterogeneous group of malignancies with a lack of data of high-level evidence.
Methods; Clinical data of 127 patients treated for SGC at a university cancer center between 2002 and 2017 were analyzed retrospectively. The association of clinicopathological characteristics, treatment modalities, adverse events, and outcome was assessed.
Results: Patients received surgery (n = 65), surgery followed by (chemo-)radiotherapy (n = 56), or primary (chemo-)radiotherapy (n = 6). Injury to the cranial nerves or their branches was the most frequent surgical complication affecting 40 patients (33.1%). Ten year overall and progression-free survival rates were 73.2% and 65.4%, respectively. Parotid tumor site, advanced tumor, and positive nodal stage remained independent negative prognostic factors for overall survival, loco-regional and distant tumor control in multivariate analysis.
Conclusions: Optimizing treatment strategies for SGC, depending on distinct clinicopathological factors, remains challenging due to the low incidence rates of the disease.
Introduction: Recent animal studies have shown that the alternate renin-angiotensin system (RAS) consisting of angiotensin-converting enzyme 2 (ACE2), angiotensin-(1–7) (Ang-(1–7)) and the Mas receptor is upregulated in cirrhosis and contributes to splanchnic vasodilatation and portal hypertension. To determine the potential relevance of these findings to human liver disease, we evaluated its expression and relationship to the patients’ clinical status in subjects with cirrhosis. Methods: Blood sampling from peripheral and central vascular beds was performed intra-operatively for cirrhotic patients at the time of liver transplantation (LT) or trans-jugular intra-hepatic portosystemic shunt (TIPS) procedures to measure angiotensin II (Ang II) and Ang-(1–7) peptide levels and ACE and ACE2 enzyme activity. Relevant clinical and hemodynamic data were recorded pre-operatively for all subjects and peripheral blood sampling was repeated 3 months or later post-operatively. Results: Ang-(1–-7) and ACE2 activity were up-regulated more than twofold in cirrhotic subjects both at the time of LT and TIPS and levels returned to comparable levels as control subjects post-transplantation. Ang-(1–7) levels correlated positively with the degree of liver disease severity, as measured by the model for an end-stage liver disease (MELD) and also with clinical parameters of pathological vasodilatation including cardiac output (CO). There were strong correlations found between the ACE2:ACE and the Ang-(1–7):Ang II ratio highlighting the inter-dependence of the alternate and classical arms of the RAS and thus their potential impact on vascular tone. Conclusions: In human cirrhosis, the alternate RAS is markedly upregulated and the activation of this system is associated strongly with features of the hyperdynamic circulation in advanced human cirrhosis.
Background & Aims: Liver fibrosis arises from long-term chronic liver injury, accompanied by an accelerated wound healing response with interstitial accumulation of extracellular matrix (ECM). Activated hepatic stellate cells (HSC) are the main source for ECM production. MicroRNA29a (miR-29a) is a crucial antifibrotic miRNA that is repressed during fibrosis, resulting in up-regulation of collagen synthesis.
Methods; Intracellular and extracellular miRNA levels of primary and immortalized myofibroblastic HSC in response to profibrogenic stimulation by transforming growth factor β (TGFβ) or platelet-derived growth factor-BB (PDGF-BB) or upon inhibition of vesicular transport and autophagy processes were determined by quantitative polymerase chain reaction. Autophagy flux was studied by electron microscopy, flow cytometry, immunoblotting, and immunocytochemistry. Hepatic and serum miR-29a levels were quantified by using both liver tissue and serum samples from a cohort of chronic hepatitis C virus patients and a murine CCl4 induced liver fibrosis model.
Results: In our study, we show that TGFβ and PDGF-BB resulted in decrease of intracellular miR-29a and a pronounced increase of vesicular miR-29a release into the supernatant. Strikingly, miR-29a vesicular release was accompanied by enhanced autophagic activity and up-regulation of the autophagy marker protein LC3. Moreover, autophagy inhibition strongly prevented miR-29a secretion and repressed its targets’ expression such as Col1A1. Consistently, hepatic miR-29a loss and increased LC3 expression in myofibroblastic HSC were associated with increased serum miR-29a levels in CCl4-treated murine liver fibrosis and specimens of hepatitis C virus patients with chronic liver disease.
Conclusions: We provide evidence that activation-associated autophagy in HSC induces release of miR-29a, whereas inhibition of autophagy represses fibrogenic gene expression in part through attenuated miR-29a secretion.
Despite multidisciplinary local and systemic therapeutic approaches, the prognosis for most patients with brain metastases is still dismal. The role of adaptive and innate anti-tumor response including the Human Leukocyte Antigen (HLA) machinery of antigen presentation is still unclear. We present data on the HLA class II-chaperone molecule CD74 in brain metastases and its impact on the HLA peptidome complexity.
We analyzed CD74 and HLA class II expression on tumor cells in a subset of 236 human brain metastases, primary tumors and peripheral metastases of different entities in association with clinical data including overall survival. Additionally, we assessed whole DNA methylome profiles including CD74 promoter methylation and differential methylation in 21 brain metastases. We analyzed the effects of a siRNA mediated CD74 knockdown on HLA-expression and HLA peptidome composition in a brain metastatic melanoma cell line.
We observed that CD74 expression on tumor cells is a strong positive prognostic marker in brain metastasis patients and positively associated with tumor-infiltrating T-lymphocytes (TILs). Whole DNA methylome analysis suggested that CD74 tumor cell expression might be regulated epigenetically via CD74 promoter methylation. CD74high and TILhigh tumors displayed a differential DNA methylation pattern with highest enrichment scores for antigen processing and presentation. Furthermore, CD74 knockdown in vitro lead to a reduction of HLA class II peptidome complexity, while HLA class I peptidome remained unaffected.
In summary, our results demonstrate that a functional HLA class II processing machinery in brain metastatic tumor cells, reflected by a high expression of CD74 and a complex tumor cell HLA peptidome, seems to be crucial for better patient prognosis.
Several lines of evidence suggest the ligand-sensing transcription factor Nurr1 as a promising target to treat neurodegenerative diseases. Nurr1 modulators to validate and exploit this therapeutic potential are rare, however. To identify novel Nurr1 agonist chemotypes, we have employed the Nurr1 activator amodiaquine as template for microscale analogue library synthesis. The first set of analogues was based on the 7-chloroquiolin-4-amine core fragment of amodiaquine and revealed superior N-substituents compared to diethylaminomethylphenol contained in the template. A second library of analogues was subsequently prepared to replace the chloroquinolineamine scaffold. The two sets of analogues enabled a full scaffold hop from amodiaquine to a novel Nurr1 agonist sharing no structural features with the lead but comprising superior potency on Nurr1. Additionally, pharmacophore modeling based on the entire set of active and inactive analogues suggested key features for Nurr1 agonists.
Background: There is an urgent need for expanding and enhancing autism spectrum disorder (ASD) samples, in order to better understand causes of ASD.
Methods: In a unique public-private partnership, 13 sites with extensive experience in both the assessment and diagnosis of ASD embarked on an ambitious, 2-year program to collect samples for genetic and phenotypic research and begin analyses on these samples. The program was called The Autism Simplex Collection (TASC). TASC sample collection began in 2008 and was completed in 2010, and included nine sites from North America and four sites from Western Europe, as well as a centralized Data Coordinating Center.
Results: Over 1,700 trios are part of this collection, with DNA from transformed cells now available through the National Institute of Mental Health (NIMH). Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule-Generic (ADOS-G) measures are available for all probands, as are standardized IQ measures, Vineland Adaptive Behavioral Scales (VABS), the Social Responsiveness Scale (SRS), Peabody Picture Vocabulary Test (PPVT), and physical measures (height, weight, and head circumference). At almost every site, additional phenotypic measures were collected, including the Broad Autism Phenotype Questionnaire (BAPQ) and Repetitive Behavior Scale-Revised (RBS-R), as well as the non-word repetition scale, Communication Checklist (Children's or Adult), and Aberrant Behavior Checklist (ABC). Moreover, for nearly 1,000 trios, the Autism Genome Project Consortium (AGP) has carried out Illumina 1 M SNP genotyping and called copy number variation (CNV) in the samples, with data being made available through the National Institutes of Health (NIH). Whole exome sequencing (WES) has been carried out in over 500 probands, together with ancestry matched controls, and this data is also available through the NIH. Additional WES is being carried out by the Autism Sequencing Consortium (ASC), where the focus is on sequencing complete trios. ASC sequencing for the first 1,000 samples (all from whole-blood DNA) is complete and data will be released in 2014. Data is being made available through NIH databases (database of Genotypes and Phenotypes (dbGaP) and National Database for Autism Research (NDAR)) with DNA released in Dist 11.0. Primary funding for the collection, genotyping, sequencing and distribution of TASC samples was provided by Autism Speaks and the NIH, including the National Institute of Mental Health (NIMH) and the National Human Genetics Research Institute (NHGRI).
Conclusions: TASC represents an important sample set that leverages expert sites. Similar approaches, leveraging expert sites and ongoing studies, represent an important path towards further enhancing available ASD samples.